| Document |
Document Title |
|
WO/2023/202567A1 |
A method for refining cefotaxime sodium, comprising the following steps: (1) dissolving cefotaxime acid in a mixed solvent of water, methanol, and acetone, adding sodium acetate, and stirring to dissolve until clarification; (2) adding a...
|
|
WO/2023/070822A1 |
Provided is a process for preparing Cefazolin sodium for injection, comprising the following steps: (1) adding dichloromethane into a Cefazolin sodium crude product, adding chitosan, then adding sodium ethoxide and 5-ethyl-2-methylpyridi...
|
|
WO/2023/050596A1 |
The present invention provides a process for preparing cefuroxime sodium for injection, comprising: dissolving cefuroxime sodium in a phosphate buffer solution, using activated carbon for decolorization, and then washing the filter cake ...
|
|
WO/2023/007325A1 |
A metallo-β-lactamase (MBL) inhibitor of general formula (I) C-A-L (I) in which: C is a funtionalised aza-cycloalkane zinc chelating moiety, L is a β-lactam moiety which may be functionalised, and A is a C1-C10 linear or cyclic linker,...
|
|
WO/2022/239872A1 |
The present invention provides: a compound represented by formula (I), formula (II), or formula (IV), or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition that is to be used for inhibiting metallo-β-lactamase ...
|
|
WO/2022/234562A1 |
The present disclosure generally relates to ceftriaxone compositions for inhalation, e.g. using a nebulizer and uses thereof for the treatment of bacterial infectious diseases or conditions associated with the respiratory tract, e.g., pn...
|
|
WO/2022/217364A1 |
A new class of antibiotics, namely, mercaptoacetophenone aminohydrazones, their analogues, their method of preparation, their salts, and their use in cases of bacterial infections, either alone or with other compounds.
|
|
WO/2022/216071A1 |
The present invention provides a cephalothin derivative or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a composition for preventing hair loss or promoting hair growth, comprising same
|
|
WO/2022/152146A1 |
The present disclosure relates to a cephalosporin antibacterial compound and a preparation method therefor. The cephalosporin antibacterial compound can exhibit antibacterial activity against Gram-negative bacteria and other bacteria.
|
|
WO/2022/056401A1 |
Compositions that inhibit the HIV-1 viral infectivity factor (Vif) and methods of use thereof are provided. The disclosed compositions have inhibitory activity against Vif function and restore A3G enzymatic activity. The disclosed compos...
|
|
WO/2021/232694A1 |
A method for nickel-based catalytic synthesis of 3-decarbamoyl cefuroxime acid. The method comprises the following steps: putting 2-furyl-2-methoxyiminoacetic acid and a nickel-based catalyst into a reaction device, adding a solvent, and...
|
|
WO/2021/234094A1 |
A liquid pharmaceutical composition comprising ceftriaxone or a pharmaceutical acceptable salt or derivative thereof and at least one magnesium salt, magnesium oxide, and/or magnesium hydroxide is provided. Also provided are a method for...
|
|
WO/2021/228007A1 |
The present invention relates to a cefoperazone magnesium compound, a preparation method therefor and an application thereof. A synergistic effect can be achieved by combining cefoperazone with magnesium; cefoperazone can inhibit the syn...
|
|
WO/2021/228008A1 |
Disclosed in the present invention are a cefuroxime magnesium compound, a composition, a preparation method therefor and the use thereof. The preparation method comprises: providing a cefuroxime-containing compound, and providing a magne...
|
|
WO/2021/228006A1 |
The present invention relates to a cefotaxime-magnesium compound, a preparation method therefor, and an application thereof. Cefotaxime is combined with magnesium so as to achieve a synergistic effect. Cefotaxime inhibits the cell wall s...
|
|
WO/2021/159176A1 |
Provided herein are compounds of formula (I) which comprise a cephalosporin antibiotic (present moiety X), bonded to a piperidine diazeniumdiolate (NONOate) or a salt thereof. Also provided are compositions that include a compound descri...
|
|
WO/2021/147986A1 |
Provided are a cephalosporin compound represented by formula I-1, I-2, or I-3, a pharmaceutical composition comprising same, and use thereof as an antibacterial agent.
|
|
WO/2021/105512A1 |
This invention relates to probes for the detection of β-lactamase-type enzymatic activity. In particular, the invention relates to novel fluorogenic substrates for detecting the presence of a catalytically active β-lactamase and a dete...
|
|
WO/2021/041583A1 |
Provided herein are β-lactamase probes that can be used to identify specific types and classes of β-lactamases in a sample, and methods of use thereof.
|
|
WO/2020/263975A1 |
This disclosure provides multifunctional conjugate molecules in which at least one β-lactam antibiotic is covalently attached to a cannabinoid by means of a linker. The disclosed conjugate molecules are designed to deliver therapeutic b...
|
|
WO/2020/204715A1 |
Provided herein are compounds useful as metallo-β-lactamase (MBL) inhibitors. The compounds have a formula A–B, where A is a β-lactam antibiotic moiety comprising a bridging methylene (-CH2-) covalently attached to -B; and B is a lat...
|
|
WO/2020/206381A1 |
The present application provides novel cephem, penem, and monobactam compounds that exhibit antibiotic activity against both Gram-negative and Gram-positive bacteria, as well as compositions comprising these compounds and methods of usin...
|
|
WO/2020/172206A1 |
A method of inhibiting, reducing growth of or destroying gram positive bacteria comprising contacting the gram positive bacteria with an effective amount of a 2-(substituted-amino)-imidazole compound and with an additional antibacterial ...
|
|
WO/2020/099858A1 |
A compound of formula (Ia) and related aspects.
|
|
WO/2019/070973A1 |
Cephem and penem compounds having a styrylmethylene moiety at the 3-position in the cephem or penem ring to which a positively charged leaving group is bonded and wherein the leaving group contains a vicinal diol or is bonded to a unsubs...
|
|
WO/2019/049024A1 |
The invention relates to compounds of general formula (I), and their use for the treatment and diagnosis of degenerative disorders characterised by high cell proliferation and/or tissue degeneration.
|
|
WO/2018/233477A1 |
The present invention discloses a method for removing a carboxyl and hydroxyl protecting group of a β-lactam compound. The method is removing a carboxyl and/or hydroxyl protecting group from a protected β-lactam compound under the acti...
|
|
WO/2018/229580A1 |
The present invention relates to an improved process for the preparation of Cefovecin sodium of a Compound of Formula (1), by reacting THF Cephem Compound of Formula (6) with MAEM Compound of Formula (8).
|
|
WO/2018/177048A1 |
The present invention relates to a crystal of cephalosporin intermediate 7α-methoxy cephalothin (I) and a method for preparing same. The crystal of 7α-methoxy cephalothin (I) undergoes Cu-Ka radiation and X-ray powder diffraction expre...
|
|
WO/2018/123920A1 |
Provided are: a compound that exhibits a broad antibacterial spectrum against various bacteria, including gram-negative bacteria; and a pharmaceutical composition that has antibacterial activity against carbapenem-resistant bacteria.
|
|
WO/2018/059213A1 |
Provided are compounds interfering with SAICAR synthesis, and applications. On the basis of existing protein structure data and small molecule structure data, calculations and analysis are performed using software to screen and obtain co...
|
|
WO/2017/153892A1 |
A synthesis process of precursors of derivatives of beta-lactam compounds, said beta-lactam compounds being selected from 6-aminopenicillanic acid and 7-aminocephalosporanic acid, preferably 6-aminopenicillanic acid, comprising the follo...
|
|
WO/2017/153824A1 |
A process for alkylating the hydroxymethyl group at position -3 of 7-Amino-3- hydroxymethyl-3-cephem-4-carboxylic acid (D-7-ACA) using an alkylating agent, strong acid and a suitable solvent(s).
|
|
WO/2017/140072A1 |
Disclosed are a novel polymorphic cefuroxime sodium compound and a preparation method for crystals thereof, where the novel polymorphic cefuroxime sodium compound is prepared by employing a particle process crystal product molecular asse...
|
|
WO/2017/140074A1 |
Disclosed are a cefmenoxime hydrochloride new crystalline compound and crystallization preparation method thereof; said cefmenoxime hydrochloride new crystalline compound is formed using particle processing for molecular assembly and mor...
|
|
WO/2017/140073A1 |
Disclosed in the present invention are a cefathiamidine novel crystal compound and a crystallisation preparation method therefor, the cefathiamidine novel crystal compound being prepared using particle process crystal product molecular a...
|
|
WO/2017/136642A1 |
The present disclosure relates to compounds having antimicrobial activity, compositions comprising said compounds in combination with β-lactam antibiotics, and methods of using the compounds and compositions.
|
|
WO/2017/046756A1 |
The present invention relates to compound of formula (II) wherein R = -OCH(CH3)2, -CH3; or a pharmaceutically acceptable salt thereof. The present invention further relates to substantially pure cefixime proxetil; substantially pure cefi...
|
|
WO/2017/042188A1 |
The present invention relates to a highly convergent method for the synthesis and purification of ceftolozane and intermediates starting from 7-aminocephaiosporanic acid (7- ACA).
|
|
WO/2017/027062A1 |
The compositions of the present disclosure provide novel fluorogenic probes for use in the specific imaging and detection of mycobacteria species, and in particular β-lactam- antibiotic resistant. Specificity for mycobacteria is conferr...
|
|
WO/2017/021390A1 |
The present invention relates to the hemi sulfuric acid salt of methyl (R)-2-amino-2-(cyclohexa-1,4-dien-1-yl)acetate, also trivially referred to as the hemi sulfuric acid salt of D-dihydrophenylglycine methyl ester, to a method for the ...
|
|
WO/2017/002903A1 |
The present invention provides a compound exhibiting a strong antimicrobial spectrum against various bacteria, including gram-negative bacteria, or a pharmaceutical composition having an antimicrobial activity against carbapenem-resistan...
|
|
WO/2017/001364A1 |
The present invention relates to a process for the preparation of carbamoylamino pyrazole derivatives using diacetoxyiodobenzene (ΡhΙ(ΟΑc)2) in combination with a non-nucleophilic base.
|
|
WO/2016/201905A1 |
Disclosed is a new industrial crystallisation technique for cefuroxime sodium, wherein a supercritical fluid extraction technique is combined with conventional crystallization techniques to realize the recrystallization of cefuroxime sod...
|
|
WO/2016/175223A1 |
Provided are the following: compounds having a powerful anti-bacterial spectrum against a variety of bacteria, including gram-negative bacteria and gram-positive bacteria; and pharmaceutical compositions having antibacterial activity aga...
|
|
WO/2016/142902A1 |
The present invention provides cefixime trihydrate (I) with surface area of less than 1.2 m2/gm containing impurity A1 less than 0.5% by area percentage of HPLC. The impurity A1 is one of the stereoisomers of impurity A as depicted below.
|
|
WO/2016/128580A1 |
Provided is a synthesis of cephalosporin derivatives, characterized by the use of the new intermediates for the preparation of cephalosporin derivatives, a crystalline toluene hemi-solvate of benzhydryl (6R,7R)-7β-[(phenylacetyl)amino]-...
|
|
WO/2016/123028A1 |
The present disclosure provides compounds that include a tetrazolone derivative of a carboxyl group of an active agent. This disclosure also relates to pharmaceutical compositions that include these compounds, methods of using these comp...
|
|
WO/2016/109259A2 |
Described herein are methods for the manufacture of ceftolozane and related compounds, as well as compositions comprising the same.
|
|
WO/2016/107331A1 |
A new crystal form of a Cefathiamidine compound and a preparation method therefor. The method comprises: dissolving a Cefathiamidine compound with the purity greater than or equal to 98% in a solvent selected from methanol and the like t...
|
